SHANGHAI – Sciclone Pharmaceuticals Inc. has had a pretty good year. The company continues to grow in the double digits and has hit revenue expectations for several quarters, helping to push stock prices to a rosy $8 to $9 range from a depressed low of $4 last year.

SHANGHAI – Sciclone Pharmaceuticals Inc. has had a pretty good year. The company continues to grow in the double digits and has hit revenue expectations for several quarters, helping to push stock prices to a rosy $8 to $9 range from a depressed low of $4 last year. It has shown that it can ride out the end of a significant commercial contract with Sanofi SA without much damage, as well as live with the reality of a seemingly never-ending SEC investigation.

SHANGHAI – China has announced that it will be initiating phase I trials for Ad5-Ebov, a recombinant adenoviral Ebola vaccine co-developed by the Bioengineering Institute of the Chinese Academy of Military Medical Sciences (AMMS) and vaccine start-up Tianjin Cansino Biotechnology Inc.

SHANGHAI – China has announced that it will be initiating phase I trials for Ad5-Ebov, a recombinant adenoviral Ebola vaccine co-developed by the Bioengineering Institute of the Chinese Academy of Military Medical Sciences (AMMS) and vaccine start-up Tianjin Cansino Biotechnology Inc.

SHANGHAI – In a case that has caused a stir among the community of returnee research scientists and even the wider drug-buying public, the U.S. attorney's office has taken the unusual move of requesting a federal judge to dismiss criminal charges filed against two former Eli Lilly and Co. employees of Chinese ethnicity working in the U.S.

SHANGHAI – In a case that has caused a stir among the community of returnee research scientists and even the wider drug-buying public, the U.S. attorney's office has taken the unusual move of requesting a federal judge to dismiss criminal charges filed against two former Eli Lilly and Co. employees of Chinese ethnicity working in the U.S.

SHANGHAI – Generon Corp. Ltd., believed to be the first Chinese biotech to complete a phase II global trial for a biologic, has announced the results for its lead candidate, F-627 (benegrastim), a next-generation drug to Amgen Inc.'s Neulasta (pegfilgrastim) for the treatment of neutropenia.

SHANGHAI – Generon Corp. Ltd., believed to be the first Chinese biotech to complete a phase II global trial for a biologic, has announced the results for its lead candidate, F-627 (benegrastim), a next-generation drug to Amgen Inc.'s Neulasta (pegfilgrastim) for the treatment of neutropenia.

SHANGHAI – Adagene Inc., of Suzhou, has raised $8 million in series A financing from a consortium of backers, including Fidelity Biosciences, Fidelity Asia Growth and Wuxi Venture Fund, an investment vehicle for Wuxi Apptec. First established in 2011, Adagene, an antibody discovery company, has been quietly developing its technology and is gearing up for its next stage of development.